PhRMA Special 301 Submission 2018

The Pharmaceutical Research and Manufacturers of America (PhRMA) appreciates the opportunity to provide this submission for the 2018 Special 301 Report. Established by the Trade Act of 1974, the Special 301 review gives the Administration a critical tool to address damaging market access and intellectual property barriers abroad that harm America’s leading innovative and creative industries and the more than 45 million jobs they support across the country.

This website uses cookies and other tracking technologies to optimize performance, preferences, usage, and statistics. By clicking “Accept All”, you consent to store on your device the cookies and other tracking technologies that require consent. You can tailor or change your preferences by clicking “Manage My Cookies”. You can check our privacy policy for more information.